We serve Chemical Name:2-pyridin-3-ylthiomorpholine CAS:951623-85-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-pyridin-3-ylthiomorpholine
CAS.NO:951623-85-1
Synonyms:AR1253;3-(Thiomorpholin-2-yl)pyridine;2-PYRIDIN-3-YL THIOMORPHOLINE
Molecular Formula:C9H12N2S
Molecular Weight:180.27000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:50.22000
Exact Mass:180.07200
LogP:1.78790
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like AR1253 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-PYRIDIN-3-YL THIOMORPHOLINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-PYRIDIN-3-YL THIOMORPHOLINE Use and application,AR1253 technical grade,usp/ep/jp grade.
Related News: South Korea and Japan are barring noncitizens who traveled recently to Hubei, the province at the center of the outbreak. 2-pyridin-3-ylthiomorpholine manufacturer Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 2-pyridin-3-ylthiomorpholine supplier Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2-pyridin-3-ylthiomorpholine vendor The fine chemical industry includes fine chemicals and special chemicals. Fine chemical products have the characteristics of a small amount of production, relatively specific application fields, and long and complex industrial chains. They are mainly used in medicine, pesticides, dyes, liquid crystals and other fields. 2-pyridin-3-ylthiomorpholine factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.
